Clinical value of minor responses after 4 doses of rituximab in Waldenström macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial

od Gertz, Morie A., Abonour, Rafat, Heffner, Leonard T., Greipp, Philip R., Uno, Hajime, Rajkumar, S. V.
Izdano 2009

Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation

od Jillella, Anand P., Arellano, Martha L., Heffner, Leonard T., Gaddh, Manila, Langston, Amelia A., Khoury, Hanna J., Mangoankar, Abhishek, Kota, Vamsi K.
Izdano u Hematol Rep (2017)

ERRATUM: Managing acute promyelocytic leukemia in patients belonging to the Jehovah’s Witness congregation

od Jillella, Anand P., Arellano, Martha L., Heffner, Leonard T., Gaddh, Manila, Langston, Amelia A., Khoury, Hanna J., Mangaonkar, Abhishek, Kota, Vamsi K.
Izdano u Hematol Rep (2019)

Phase I study of samalizumab in chronic lymphocytic leukemia and multiple myeloma: blockade of the immune checkpoint CD200

od Mahadevan, Daruka, Lanasa, Mark C., Farber, Charles, Pandey, Manjari, Whelden, Maria, Faas, Susan J., Ulery, Terrie, Kukreja, Anjli, Li, Lan, Bedrosian, Camille L., Zhang, Xiaoping, Heffner, Leonard T.
Izdano u J Immunother Cancer (2019)

Long-Term Follow-Up Results of Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy and Risk-Adapted Maintenance Approach in Newly Diagnosed Multiple Myeloma

od Joseph, Nisha S., Kaufman, Jonathan L., Dhodapkar, Madhav V., Hofmeister, Craig C., Almaula, Dhwani K., Heffner, Leonard T., Gupta, Vikas A., Boise, Lawrence H., Lonial, Sagar, Nooka, Ajay K.
Izdano u J Clin Oncol (2020)

Phase 1 Multicenter Study of Vincristine Sulfate Liposomes Injection and Dexamethasone in Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia

od Thomas, Deborah A., Kantarjian, Hagop M., Stock, Wendy, Heffner, Leonard T., Faderl, Stefan, Garcia-Manero, Guillermo, Ferrajoli, Alessandra, Wierda, William, Pierce, Sherry, Lu, Biao, Deitcher, Steven R., O’Brien, Susan
Izdano u Cancer (2009)

Venetoclax for chronic lymphocytic leukaemia patients who progress after more than one B‐cell receptor pathway inhibitor

od Wierda, William G., Byrd, John C., Davids, Matthew S., Furman, Richard R., Cheson, Bruce D., Barr, Paul M., Eradat, Herbert, Heffner, Leonard, Zhou, Lang, Verdugo, Maria, Potluri, Jalaja, Choi, Michael
Izdano u Br J Haematol (2018)

Functional profiling of venetoclax sensitivity can predict clinical response in multiple myeloma

od Matulis, Shannon M., Gupta, Vikas A., Neri, Paola, Bahlis, Nizar J., Maciag, Paulo, Leverson, Joel D., Heffner, Leonard T., Lonial, Sagar, Nooka, Ajay K., Kaufman, Jonathan L., Boise, Lawrence H.
Izdano u Leukemia (2019)

Outcomes of Chronic Phase Chronic Myeloid Leukemia after Treatment with Multiple Tyrosine Kinase Inhibitors

od Kong, Jee Hyun, Winton, Elliott F., Heffner, Leonard T., Gaddh, Manila, Hill, Brittany, Neely, Jessica, Hatcher, Angela, Joseph, Meena, Arellano, Martha, El-Rassi, Fuad, Kim, Audrey, Khoury, Jean Hanna, Kota, Vamsi K.
Izdano u J Clin Med (2020)

Combining carfilzomib and panobinostat to treat relapsed/refractory multiple myeloma: results of a Multiple Myeloma Research Consortium Phase I Study

od Kaufman, Jonathan L., Mina, Roberto, Jakubowiak, Andrzej J., Zimmerman, Todd L., Wolf, Jeffrey J., Lewis, Colleen, Gleason, Charise, Sharp, Cathy, Martin, Thomas, Heffner, Leonard T., Nooka, Ajay K., Harvey, R. Donald, Lonial, Sagar
Izdano u Blood Cancer J (2019)

Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy

od Coutre, Steven, Choi, Michael, Furman, Richard R., Eradat, Herbert, Heffner, Leonard, Jones, Jeffrey A., Chyla, Brenda, Zhou, Lang, Agarwal, Suresh, Waskiewicz, Tina, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Wierda, William G., Davids, Matthew S.
Izdano u Blood (2018)

Loncastuximab tesirine, an anti-CD19 antibody-drug conjugate, in relapsed/refractory B-cell acute lymphoblastic leukemia

od Jain, Nitin, Stock, Wendy, Zeidan, Amer, Atallah, Ehab, McCloskey, James, Heffner, Leonard, Tomlinson, Benjamin, Bhatnagar, Bhavana, Feingold, Jay, Ungar, David, Chao, Grace, Zhang, Xiaoyan, Qin, Yajuan, Havenith, Karin, Kantarjian, Hagop, Wieduwilt, Matthew J.
Izdano u Blood Adv (2020)

Molecular response with blinatumomab in relapsed/refractory B-cell precursor acute lymphoblastic leukemia

od Gökbuget, Nicola, Kantarjian, Hagop M., Brüggemann, Monika, Stein, Anthony S., Bargou, Ralf C., Dombret, Hervé, Fielding, Adele K., Heffner, Leonard, Rigal-Huguet, Françoise, Litzow, Mark, O’Brien, Susan, Zugmaier, Gerhard, Gao, Shan, Nagorsen, Dirk, Forman, Stephen J., Topp, Max S.
Izdano u Blood Adv (2019)

A Phase II Study of Bortezomib Added to Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients with Previously Untreated Indolent non-Hodgkin’s Lymphoma...

od Cohen, Jonathon B., Switchenko, Jeffrey M., Koff, Jean L., Sinha, Rajni, Kaufman, Jonathan L., Khoury, H. Jean, Bumpers, Nassoma, Colbert, Amanda, Hutchison-Rzepka, Amanda, Nastoupil, Loretta J., Heffner, Leonard T., Langston, Amelia, Lechowicz, Mary Jo, Lonial, Sagar, Flowers, Christopher R.
Izdano u Br J Haematol (2015)

Long-term follow-up from a phase 1/2 study of single-agent bortezomib in relapsed systemic AL amyloidosis

od Reece, Donna E., Hegenbart, Ute, Sanchorawala, Vaishali, Merlini, Giampaolo, Palladini, Giovanni, Bladé, Joan, Fermand, Jean-Paul, Hassoun, Hani, Heffner, Leonard, Kukreti, Vishal, Vescio, Robert A., Pei, Lixia, Enny, Christopher, Esseltine, Dixie-Lee, van de Velde, Helgi, Cakana, Andrew, Comenzo, Raymond L.
Izdano 2014

Utility of positron emission tomography-computed tomography in patients with chronic lymphocytic leukemia following B-cell receptor pathway inhibitor therapy

od Mato, Anthony R., Wierda, William G., Davids, Matthew S., Cheson, Bruce D., Coutre, Steven E., Choi, Michael, Furman, Richard R., Heffner, Leonard, Barr, Paul M., Eradat, Herbert, Ford, Sharanya M., Zhou, Lang, Verdugo, Maria, Humerickhouse, Rod A., Potluri, Jalaja, Byrd, John C.
Izdano u Haematologica (2019)

Gain of Chromosome 1q is associated with early progression in multiple myeloma patients treated with lenalidomide, bortezomib, and dexamethasone

od Schmidt, Timothy M., Barwick, Benjamin G., Joseph, Nisha, Heffner, Leonard T., Hofmeister, Craig C., Bernal, Leon, Dhodapkar, Madhav V., Gupta, Vikas A., Jaye, David L., Wu, Jiayi, Goyal, Subir, Chen, Zhengjia, Boise, Lawrence H., Lonial, Sagar, Nooka, Ajay K., Kaufman, Jonathan L.
Izdano u Blood Cancer J (2019)

Final results of a phase 1 study of loncastuximab tesirine in relapsed/refractory B-cell non-Hodgkin lymphoma

od Hamadani, Mehdi, Radford, John, Carlo-Stella, Carmelo, Caimi, Paolo F., Reid, Erin, O’Connor, Owen A., Feingold, Jay M., Ardeshna, Kirit M., Townsend, William, Solh, Melhem, Heffner, Leonard T., Ungar, David, Wang, Luqiang, Boni, Joseph, Havenith, Karin, Qin, Yajuan, Kahl, Brad S.
Izdano u Blood (2021)

Risk factors and kinetics of thrombocytopenia associated with bortezomib for relapsed, refractory multiple myeloma

od Lonial, Sagar, Waller, Edmund K., Richardson, Paul G., Jagannath, Sundar, Orlowski, Robert Z., Giver, Cynthia R., Jaye, David L., Francis, Dixil, Giusti, Sara, Torre, Claire, Barlogie, Bart, Berenson, James R., Singhal, Seema, Schenkein, David P., Esseltine, Dixie-Lee W., Anderson, Jessica, Xiao, Hugh, Heffner, Leonard T., Anderson, Kenneth C.
Izdano 2005

High-Dose Vincristine Sulfate Liposome Injection for Advanced, Relapsed, and Refractory Adult Philadelphia Chromosome–Negative Acute Lymphoblastic Leukemia

od O'Brien, Susan, Schiller, Gary, Lister, John, Damon, Lloyd, Goldberg, Stuart, Aulitzky, Walter, Ben-Yehuda, Dina, Stock, Wendy, Coutre, Steven, Douer, Dan, Heffner, Leonard T., Larson, Melissa, Seiter, Karen, Smith, Scott, Assouline, Sarit, Kuriakose, Philip, Maness, Lori, Nagler, Arnon, Rowe, Jacob, Schaich, Markus, Shpilberg, Ofer, Yee, Karen, Schmieder, Guenter, Silverman, Jeffrey A., Thomas, Deborah, Deitcher, Steven R., Kantarjian, Hagop
Izdano u J Clin Oncol (2013)